<DOC>
	<DOCNO>NCT00884962</DOCNO>
	<brief_summary>This multi-center , open-label , non-controlled Pilot Study . Approximately 24 patient assign one 3 treatment group ( 8 patient group ) . Patients group receive 2 , 4 , 6 ( 3 follow retreatment 3 ) subsegmental treatment , respectively . All patient receive treatment single lung conscious sedation general anesthesia . Patients follow 24 week completion PLVR treatment ( ) . Upon completion 12-week follow-up , safety efficacy data analyze determine effective treatment dose . Thereafter , Group 1 patient may elect retreat additional site total dose receive consistent effective dose . All study patient receive standard medical therapy addition PLVR .</brief_summary>
	<brief_title>A Dose Ranging Study Aeris Polymeric Lung Volume Reduction ( PLVR ) System Patients With Advanced Upper Lobe Predominant Emphysema</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Patients must diagnosis advanced upper lobe predominant ( ULP ) emphysema advance disease superior low lobe define FEV1/FVC &lt; 70 % predict , FEV1 &lt; 50 % predict , TLC &gt; 100 % predict , RV &gt; 135 % predict . Patients must persistent symptom despite medical therapy either candidate Lung Volume Reduction Surgery ( LVRS ) elect undergo LVRS . Patients must &gt; 40 year age , symptom despite medical therapy , none prespecified comorbid condition could influence study outcome ability tolerate bronchoscopy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>emphysema</keyword>
	<keyword>aeris</keyword>
	<keyword>PLVR</keyword>
	<keyword>BLVR</keyword>
	<keyword>germany</keyword>
	<keyword>treatment</keyword>
	<keyword>device</keyword>
	<keyword>breathing</keyword>
</DOC>